CPDR Updates Its Prostate Cancer Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

ROCKVILLE, Maryland-The website for the Center for Prostate Disease Research (CPDR) has a whole new look. Stephen Doyle, an experienced graphic artist, has updated and redesigned the site to be a user-friendly tool for patients, clinicians, scientists, and the general public to find information about prostate cancer and related diseases.

ROCKVILLE, Maryland—The website for the Center for Prostate Disease Research (CPDR) has a whole new look. Stephen Doyle, an experienced graphic artist, has updated and redesigned the site to be a user-friendly tool for patients, clinicians, scientists, and the general public to find information about prostate cancer and related diseases.

CPDR director Judd W. Moul, MD, a colonel in the Army Medical Department, commented, "Previously, the content was sound, but there was not as much in terms of presentation. Now, my patients say that it has great readability and visual appeal." To visit the CPDR website, go to www.cpdr.org. 

Articles in this issue
Elderly Colon Cancer Patients Benefit From Adjuvant Chemotherapy
Stromal Cells May Be Involved in Development of Breast Carcinoma
Intercultural Facts About Cancer
Nurse-Provided Education Crucial to Sural Nerve Graft Prostatectomy Patients
18-Gene Cluster Found in ER-Positive Breast Cancers
Viread OK’d for Treating HIV With Other Antiretrovirals
Surgeons in New York Operate on Patient in France
Fulvestrant Reduces Cell Turnover Index More Than Tamoxifen
New Lung Cancer Campaign Launched
CPDR Updates Its Prostate Cancer Website
NIAID Begins Phase I Trial of a DNA-Based HIV Vaccine
PET Used to Measure Efficacy of an Angiogenesis Inhibitor
Avon Donates $20 Million to NCI for Cancer Research
Weekly Gemcitabine/Vinorelbine Proves Effective in NSCLC
Supplemental NDA Submitted for Gleevec
Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer

Tim Cortese
November 21st 2024
Article

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

SBRT Emerges as Viable Treatment for Localized Prostate Cancer

Tim Cortese
November 12th 2024
Article

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Darolutamide/ADT Improves rPFS in Metastatic HSPC

Jonah Feldman
October 13th 2024
Article

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

Roman Fabbricatore
October 11th 2024
Article

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.